PT  - JOURNAL ARTICLE
AU  - McCreary, Erin K.
AU  - Bariola, J. Ryan
AU  - Minnier, Tami
AU  - Wadas, Richard J.
AU  - Shovel, Judith A.
AU  - Albin, Debbie
AU  - Marroquin, Oscar C.
AU  - Kip, Kevin E.
AU  - Collins, Kevin
AU  - Schmidhofer, Mark
AU  - Wisniewski, Mary Kay
AU  - Nace, David A
AU  - Sullivan, Colleen
AU  - Axe, Meredith
AU  - Meyer, Russell
AU  - Weissman, Alexandra
AU  - Garrard, William
AU  - Peck-Palmer, Octavia M.
AU  - Wells, Alan
AU  - Bart, Robert D.
AU  - Yang, Anne
AU  - Berry, Lindsay
AU  - Berry, Scott
AU  - Crawford, Amy
AU  - McGlothin, Anna
AU  - Khadem, Tina
AU  - Linstrum, Kelsey
AU  - Montgomery, Stephanie K.
AU  - Ricketts, Daniel
AU  - Kennedy, Jason N.
AU  - Pidro, Caroline J.
AU  - Haidar, Ghady
AU  - Snyder, Graham M.
AU  - McVerry, Bryan J.
AU  - Angus, Derek C.
AU  - Kip, Paula L.
AU  - Seymour, Christopher W.
AU  - Huang, David T.
TI  - A Learning Health System Randomized Trial of Monoclonal Antibodies for Covid-19
AID  - 10.1101/2021.09.03.21262551
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.09.03.21262551
4099  - http://medrxiv.org/content/early/2021/09/09/2021.09.03.21262551.short
4100  - http://medrxiv.org/content/early/2021/09/09/2021.09.03.21262551.full
AB  - Background Neutralizing monoclonal antibodies (mAb) targeting SARS-CoV-2 decrease hospitalization and death in patients with mild to moderate Covid-19. Yet, their clinical use is limited, and comparative effectiveness is unknown.Methods We present the first results of an ongoing, learning health system adaptive platform trial to expand mAb treatment to all eligible patients and evaluate the comparative effectiveness of available mAbs. The trial launched March 10, 2021. Results are reported as of June 25, 2021 due to the U.S. federal decision to pause distribution of bamlanivimab-etesevimab; patient follow-up concluded on July 23, 2021. Patients referred for mAb who met Emergency Use Authorization criteria were provided a random mAb allocation of bamlanivimab, bamlanivimab-etesevimab, or casirivimab-imdevimab with a therapeutic interchange policy. The primary outcome was hospital-free days (days alive and free of hospital) within 28 days, where patients who died were assigned -1 day. The primary analysis was a Bayesian cumulative logistic model of all patients treated at an infusion center or emergency department, adjusting for treatment location, age, sex, and time. Inferiority was defined as a 99% posterior probability of an odds ratio < 1. Equivalence was defined as a 95% posterior probability that the odds ratio is within a given bound.Results Prior to trial launch, 3.1% (502) of 16,345 patients who were potentially eligible by an automated electronic health record (EHR) screen received mAb. During the trial period, 23.2% (1,201) of 5,173 EHR-screen eligible patients were treated, a 7.5-fold increase. After including additional referred patients from outside the health system, a total of 1,935 study patients received mAb therapy (128 bamlanivimab, 885 bamlanivimab-etesevimab, 922 casirivimab-imdevimab). Mean age ranged from 55 to 57 years, half were female (range, 53% to 54%), and 17% were Black (range, 12% to 19%). Median hospital–free days were 28 (IQR, 28 to 28) for each mAb group. Hospitalization varied between groups (bamlanivimab, 12.5%; bamlanivimab-etesevimab, 14.7%, casirivimab-imdevimab, 14.3%). Relative to casirivimab-imdevimab, the median adjusted odds ratios were 0.58 (95% credible interval (CI), 0.30 to 1.16) and 0.94 (95% CI, 0.72 to 1.24) for the bamlanivimab and bamlanivimab-etesevimab groups, respectively. These odds ratios yielded 91% and 94% probabilities of inferiority of bamlanivimab versus bamlanivimab-etesevimab and casirivimab-imdevimab respectively, and an 86% probability of equivalence between bamlanivimab-etesevimab and casirivimab-imdevimab, at the prespecified odds ratio bound of 0.25. Twenty-one infusion-related adverse events occurred in 0% (0/128), 1.4% (12/885), and 1.0% (9/922) of patients treated with bamlanivimab, bamlanivimab-etesevimab, and casirivimab-imdevimab, respectively.Conclusion In non-hospitalized patients with mild to moderate Covid-19, bamlanivimab, compared to bamlanivimab-etesevimab and casirivimab-imdevimab, resulted in 91% and 94% probabilities of inferiority with regards to odds of improvement in hospital-free days within 28 days. There was an 86% probability of equivalence between bamlanivimab-etesevimab and casirivimab-imdevimab at an odds ratio bound of 0.25. However, the trial was unblinded early due to federal distribution decisions, and no mAb met prespecified criteria for statistical inferiority or equivalence. (ClinicalTrials.gov, NCT04790786).Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04790786Clinical Protocols https://pubmed.ncbi.nlm.nih.gov/34034784/ Funding StatementThis work received no external funding. Internal funding from the UPMC Hospital System had no control over the study. The U.S. federal government provided the monoclonal antibody treatments reported in this manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The project underwent review and was granted ethical approvals by the UPMC Quality Improvement Review Committee (Project ID: 3280) and the University of Pittsburgh Institutional Review Board (Study ID: 21020179) the ethics, regulatory, and legal oversight bodies for protecting patient/participant rights, confidentiality, consent (including waiver of consent), and the analysis and dissemination of deidentified data within the UPMC system.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will not be made available.AEAdverse EventsBbamlanivimabB + Ebamlanivimab and etesevimabBMIBody Mass IndexC + Icasirivimab + imdevimabCDCCenters for Disease Control and PreventionCOPDChronic Obstructive Pulmonary DiseaseCOVID-19Coronavirus disease 2019CVDCardiovascular DiseaseEUAEmergency Use AuthorizationFDAFood and Drug AdministrationHHSHealth and Human ServicesHFDHospital Free DaysHTNHypertensionkDaKilodaltonsIgG1Immunoglobulin G1KGKilogramsmABMonoclonal AntibodiesPCRPolymerase Chain ReactionSAEsSerious Adverse EventsSARS-CoV-SevereAcute Respiratory Syndrome 2 Coronavirus 2UATRCUPMC Antibody Treatment and Evaluation CenterAEAdverse EventsBMIBody Mass IndexC + Icasirivimab + imdevimabCDCCenters for Disease Control and PreventionCOPDChronic Obstructive Pulmonary DiseaseCOVID-19Coronavirus disease 2019CVDCardiovascular DiseaseEUAEmergency Use AuthorizationFDAFood and Drug AdministrationHHSHealth and Human ServicesHFDHospital Free DaysHTNHypertensionkDaKilodaltonsIgG1Immunoglobulin G1KGKilogramsOPTIMISE-C19OPtimizing Treatment and Impact of Monoclonal antIbodieS through EvaluationmABMonoclonal AntibodiesPCRPolymerase Chain ReactionSAEsSerious Adverse EventsSARS-CoV-2Severe Acute Respiratory Syndrome Coronavirus 2UATRCUPMC Antibody Treatment and Evaluation CenterVir-7831sotrovimab